Janney Montgomery Scott LLC lifted its position in shares of Humana Inc. (NYSE:HUM – Get Rating) by 7.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,089 shares of the insurance provider’s stock after acquiring an additional 642 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Humana were worth $4,656,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of HUM. Arlington Partners LLC acquired a new position in Humana during the 4th quarter worth about $29,000. WFA of San Diego LLC acquired a new position in Humana during the 4th quarter worth about $33,000. SJS Investment Consulting Inc. lifted its holdings in Humana by 1,257.1% during the 4th quarter. SJS Investment Consulting Inc. now owns 95 shares of the insurance provider’s stock worth $49,000 after buying an additional 88 shares during the period. Affiance Financial LLC acquired a new position in Humana during the 4th quarter worth about $50,000. Finally, Accurate Wealth Management LLC acquired a new position in Humana during the 4th quarter worth about $55,000. Institutional investors and hedge funds own 93.38% of the company’s stock.
Insider Buying and Selling at Humana
In other news, insider Joseph C. Ventura sold 2,048 shares of the stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $507.97, for a total transaction of $1,040,322.56. Following the completion of the sale, the insider now directly owns 4,256 shares in the company, valued at $2,161,920.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Bruce D. Broussard sold 17,575 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $505.85, for a total value of $8,890,313.75. Following the completion of the transaction, the chief executive officer now directly owns 70,040 shares in the company, valued at approximately $35,429,734. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joseph C. Ventura sold 2,048 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $507.97, for a total transaction of $1,040,322.56. Following the completion of the transaction, the insider now owns 4,256 shares of the company’s stock, valued at $2,161,920.32. The disclosure for this sale can be found here. Company insiders own 0.32% of the company’s stock.
Humana Stock Up 0.2 %
Humana (NYSE:HUM – Get Rating) last released its earnings results on Wednesday, February 1st. The insurance provider reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.16. The business had revenue of $22.44 billion for the quarter, compared to analysts’ expectations of $22.45 billion. Humana had a return on equity of 20.50% and a net margin of 3.02%. The firm’s revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.24 earnings per share. As a group, research analysts expect that Humana Inc. will post 28.07 earnings per share for the current fiscal year.
Humana Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Shareholders of record on Friday, June 30th will be given a dividend of $0.885 per share. The ex-dividend date is Thursday, June 29th. This represents a $3.54 annualized dividend and a yield of 0.72%. Humana’s payout ratio is 16.06%.
Analyst Upgrades and Downgrades
HUM has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on Humana in a research report on Thursday. They issued an “overweight” rating and a $597.00 price objective for the company. TheStreet raised Humana from a “c+” rating to a “b-” rating in a research report on Thursday, April 13th. Stephens lowered their price objective on Humana from $625.00 to $590.00 and set an “overweight” rating for the company in a research report on Friday, February 3rd. JPMorgan Chase & Co. lowered their price objective on Humana from $630.00 to $625.00 and set an “overweight” rating for the company in a research report on Friday, January 6th. Finally, Truist Financial lifted their price objective on Humana from $560.00 to $590.00 and gave the stock a “hold” rating in a research report on Thursday, April 13th. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $596.89.
Humana Profile
Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.
Read More
- Get a free copy of the StockNews.com research report on Humana (HUM)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Get Rating).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
